Glenmark Mexico – Eugenio Garcia Verde, General Manager
Eugenio Garcia Verde, general manager at Glenmark Mexico, reveals the company’s ambitious aim to see the brand amongst the top 40 in Mexico and top 20 worldwide by 2020. …
Founded in India in 1977, today Glenmark is a leading player in the discovery of new molecules, with a significant presence in branded generics markets across emerging economies and APIs in regulated and semi-regulated countries. Glenmark employs over 10,400 people in over 80 countries, relies on 14 manufacturing facilities in four countries (India, Argentina, Czech and Brazil) and 6 R&D centres (India, UK and Switzerland). In Mexico the company was constituted back in 2008 with commercial operations starting in 2009.
Contact details
Torre Diamante
Insurgentes Sur 1685 Piso 9 Desp. 903.
Col. Guadalupe Inn, Del. Álvaro Obregón
CP 01020, México DF
MEXICO
Tel: +52 (55) 5663-0554
Website: www. glenmarkpharma.com
Eugenio Garcia Verde, general manager at Glenmark Mexico, reveals the company’s ambitious aim to see the brand amongst the top 40 in Mexico and top 20 worldwide by 2020. …
Lundbeck Mexico GM Oscar Parra discusses raising awareness of depression in Mexico, Lundbeck’s innovative treatments for depression and Alzheimer’s, and managing to navigate the country’s regulatory process to ultimately benefit…
Daniel Pardo Bejarano, CEO of BOMI Mexico, details the competitive advantages and the unique business approach that make BOMI the logistics partner of choice of the Mexican healthcare industry, while…
In light of the recently released OECD Reviews of Health Systems: Mexico 2016, Roberto Martinez, general director of the OECD Mexico Center for Latin America, reveals the OECD’s key findings…
Gabriel O’Shea, National Commissioner of Seguro Popular, on how the institute generates more efficient and transparent resource allocation across Mexico as the country prepares to implement medical service exchange among…
Francisco González, CEO of ProMéxico, the Mexican investment agency, describes the strengths of Mexico’s research and industrial base, untapped business opportunities in the pharmaceutical and healthcare sectors, and new export…
Javier Amtmann, the new president of AMIIF, the Mexican association of pharmaceutical innovators, reveals AMIIF’s strategic priorities and key areas of focus. As Chairman of the Board of Menarini Mexico,…
Xavier Valdez analyses the dynamics impacting the Mexican pharmaceutical market and explains why IMS Health is transforming itself to strengthen its position as the partner of choice for decision-makers throughout the…
The Mexican pharmaceutical market’s capacity to change dramatically in a short period of time means that both innovators and generics companies must think strategically and “play their cards right” in…
Patricia Ostrosky, general director of the Institute of Biomedical Research in Mexico, details current research subjects and calls for greater collaboration between Mexican universities and the pharmaceutical industry to bring…
Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de…
For Cristóbal Thompson, Executive Director of AMIIF, health is a formidable measure of productivity and competitiveness that Mexico can no longer overlook if it is to sustain robust economic growth. He…
Tackling both obesity and diabetes is a primary objective of the National Academy of Medicine of Mexico and requires a holistic, multidisciplinary approach, according to Dr. Graue Wiechers, president of…
See our Cookie Privacy Policy Here
